Precigen (PGEN) EBITDA (2012 - 2026)

Precigen (PGEN) has 15 years of EBITDA data on file, last reported at -$6.0 million in Q1 2026.

• On a quarterly basis, EBITDA rose 73.47% year-over-year to -$6.0 million in Q1 2026; TTM through Mar 2026 was -$93.9 million, a 29.51% increase from a year earlier, with the FY2025 full-year figure at -$110.5 million, up 18.16% from the prior year.
• EBITDA for Q1 2026 stood at -$6.0 million, up from -$21.7 million in the prior quarter.
• Over the last five years, EBITDA for PGEN reached as high as -$6.0 million in Q1 2026 and fell as low as -$60.8 million in Q2 2024.
• Historically, EBITDA has averaged -$25.1 million across 5 years, with a median of -$22.6 million in 2025.
• Across the five-year window, EBITDA slumped 188.07% in 2024 and jumped 73.47% in 2026, its largest moves.
• Year by year, EBITDA stood at -$21.8 million in 2022, then sank by 57.01% to -$34.2 million in 2023, then advanced by 16.68% to -$28.5 million in 2024, then grew by 24.02% to -$21.7 million in 2025, then surged by 72.33% to -$6.0 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$6.0 million in Q1 2026, -$21.7 million in Q4 2025, and -$34.5 million in Q3 2025.